Is Editas Stock a Buy Now?
Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at gene-editing stocks.
Data by ReportLinker shows that the gene-editing market is expected to grow from $5.3 billion this year to $10.6 billion by 2028, showing a compound annual growth rate of 15%.
Several gene-editing companies' shares are doing well. CRISPR Therapeutics is up nearly 5% this year, while Vertex Therapeutics is up more than 19%. Rocket Pharmaceuticals, while down more than 3% so far this year, is up more than 19% over the past month.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€443.75
0.010%
The stock is one of the favorites of our community with 51 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 429 € is below the current price of 443.75 € for Vertex Pharmaceuticals Inc., so the potential is actually -3.32%.
